Immunotherapy Drugs Market by Type (Checkpoint Inhibitors [Brand {Humira, Rituxan/MabThera, Herceptin, Remicade, Enbrel}], Vaccines [Type {Preventive, Therapeutic}, Brand {Prevnar/Prevenar 13, Gardasil, ProQuad, Rotarix}]), by Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases), by End User (Hospitals & Clinics, Individuals), by Geography (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa) – Global Market Size, Share, Development, Growth, and Demand Forecast, 2013–2023

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Type

1.3.2 Market Segmentation by Therapy Area

1.3.3 Market Segmentation by End User

1.3.4 Market Segmentation by Geography

1.3.5 Analysis Period

1.3.6 Market Data Reporting Unit

1.3.6.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Industry Insights

4.1 Epidemiology Analysis

4.1.1 Cancer

4.1.2 Autoimmune and Inflammatory Diseases

4.1.2.1 Autoimmune diseases

4.1.2.2 Inflammatory diseases

4.1.3 Infectious Diseases

4.2 Pricing and Reimbursement Scenario for Immunotherapy Drugs

4.2.1 Global

4.2.2 Europe

4.2.2.1 U.K.

4.2.2.2 Belgium

4.2.2.3 France

4.2.2.4 Italy

4.2.2.5 Spain

4.2.3 North America

4.2.3.1 U.S.

4.2.4 APAC

4.2.4.1 Japan

4.2.4.2 China

4.2.4.3 Australia

4.3 Research and Funding Initiatives for Immunotherapy Drugs

4.4 List of Pipeline Drugs

4.4.1 Sanofi

4.4.2 Pfizer Inc.

4.4.3 Novartis AG

4.4.4 Merck & Co. Inc.

4.4.5 Johnson & Johnson

4.4.6 GlaxoSmithKline plc

4.4.7 F. Hoffman-La Roche Ltd.

4.4.8 Eli Lilly and Company

4.4.9 Celgene Corporation

4.4.10 C. H. Boehringer Sohn AG & Co. KG

4.4.11 Bristol-Myers Squibb Company

4.4.12 AstraZeneca PLC

4.4.13 AbbVie Inc.

4.5 Treatment Protocols and Line of Therapies

4.5.1 First-Line Therapy for Treating Cancer

4.5.2 Second-Line Therapy for Treating Cancer

4.5.3 Other Treatments

4.5.3.1 Targeted therapy

4.5.3.2 Hormone therapy

Chapter 5. Introduction

5.1 Definition of Market Segments

5.1.1 By Type

5.1.1.1 Checkpoint inhibitors

5.1.1.1.1 By brand

5.1.1.1.1.1 Humira

5.1.1.1.1.2 Rituxan/MabThera

5.1.1.1.1.3 Herceptin

5.1.1.1.1.4 Remicade

5.1.1.1.1.5 Enbrel

5.1.1.1.1.6 Others

5.1.1.2 Vaccines

5.1.1.2.1 By type

5.1.1.2.1.1 Preventive vaccines

5.1.1.2.1.2 Therapeutic vaccines

5.1.1.2.2 By brand

5.1.1.2.2.1 Prevnar/ Prevenar 13

5.1.1.2.2.2 Gardasil

5.1.1.2.2.3 ProQuad

5.1.1.2.2.4 Rotarix

5.1.1.2.2.5 Others

5.1.2 By Therapy Area

5.1.2.1 Cancer

5.1.2.2 Autoimmune and inflammatory diseases

5.1.2.3 Infectious diseases

5.1.3 By End User

5.1.3.1 Hospitals and clinics

5.1.3.2 Individuals

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 Surge in the prevalence of chronic diseases

5.2.1.2 Thriving demand and development of mAbs

5.2.1.3 Rise in the implementation of target therapy

5.2.1.4 Increasing availability of biosimilars

5.2.1.5 Impact analysis of drivers on market forecast

5.2.2 Restraints

5.2.2.1 High cost of immunotherapy treatment

5.2.2.2 Impact analysis of restraints on market forecast

5.3 Porter’s Five Forces Analysis

Chapter 6. Global Market Size and Forecast

6.1 By Type

6.1.1 Checkpoint Inhibitors Market, by Brand

6.1.2 Vaccines Market, by Type

6.1.3 Vaccines Market, by Brand

6.2 By Therapy Area

6.3 By End User

6.4 By Region

Chapter 7. North America Market Size and Forecast

7.1 By Therapy Area

7.2 By End User

7.3 By Country

Chapter 8. Europe Market Size and Forecast

8.1 By Therapy Area

8.2 By End User

8.3 By Country

Chapter 9. APAC Market Size and Forecast

9.1 By Therapy Area

9.2 By End User

9.3 By Country

Chapter 10. LATAM Market Size and Forecast

10.1 By Therapy Area

10.2 By End User

10.3 By Country

Chapter 11. MEA Market Size and Forecast

11.1 By Therapy Area

11.2 By End User

11.3 By Country

Chapter 12. Competitive Landscape

12.1 Product Benchmarking of Key Players

12.2 Global Strategic Developments of Key Players

12.2.1 Mergers and Acquisitions

12.2.2 Product Launches and Approvals

12.2.3 Collaborations, Partnerships and Agreements

12.2.4 Other Developments

Chapter 13. Company Profiles

13.1 Eli Lilly and Company

13.1.1 Business Overview

13.1.2 Product and Service Offerings

13.1.2.1 Marketed products

13.1.2.2 Pipeline products

13.1.3 Key Financial Summary

13.2 Sanofi

13.2.1 Business Overview

13.2.2 Product and Service Offerings

13.2.2.1 Marketed products

13.2.2.2 Pipeline products

13.2.3 Key Financial Summary

13.3 Novartis AG

13.3.1 Business Overview

13.3.2 Product and Service Offerings

13.3.2.1 Marketed products

13.3.2.2 Pipeline products

13.3.3 Key Financial Summary

13.4 AbbVie Inc.

13.4.1 Business Overview

13.4.2 Product and Service Offerings

13.4.2.1 Marketed products

13.4.2.2 Pipeline products

13.4.3 Key Financial Summary

13.5 F. Hoffmann-La Roche Ltd.

13.5.1 Business Overview

13.5.2 Product and Service Offerings

13.5.2.1 Marketed products

13.5.2.2 Pipeline products

13.5.3 Key Financial Summary

13.6 AstraZeneca PLC

13.6.1 Business Overview

13.6.2 Product and Service Offerings

13.6.2.1 Marketed products

13.6.2.2 Pipeline products

13.6.3 Key Financial Summary

13.7 Merck & Co. Inc.

13.7.1 Business Overview

13.7.2 Product and Service Offerings

13.7.2.1 Marketed products

13.7.2.2 Pipeline products

13.7.3 Key Financial Summary

13.8 GlaxoSmithKline plc

13.8.1 Business Overview

13.8.2 Product and Service Offerings

13.8.2.1 Marketed products

13.8.2.2 Pipeline products

13.8.3 Key Financial Summary

13.9 Bristol-Myers Squibb Company

13.9.1 Business Overview

13.9.2 Product and Service Offerings

13.9.2.1 Marketed products

13.9.2.2 Pipeline products

13.9.3 Key Financial Summary

13.10 Amgen Inc.

13.10.1 Business Overview

13.10.2 Product and Service Offerings

13.10.2.1 Marketed products

13.10.2.2 Pipeline products

13.10.3 Key Financial Summary

13.11 C. H. Boehringer Sohn AG & Co. KG

13.11.1 Business Overview

13.11.2 Product and Service Offerings

13.11.2.1 Marketed products

13.11.2.2 Pipeline products

13.11.3 Key Financial Summary

13.12 Celgene Corporation

13.12.1 Business Overview

13.12.2 Product and Service Offerings

13.12.2.1 Marketed products

13.12.2.2 Pipeline products

13.12.3 Key Financial Summary

13.13 Johnson & Johnson

13.13.1 Business Overview

13.13.2 Product and Service Offerings

13.13.2.1 Marketed products

13.13.2.2 Pipeline products

13.13.3 Key Financial Summary

13.14 Takeda Pharmaceutical Company Limited

13.14.1 Business Overview

13.14.2 Product and Service Offerings

13.14.2.1 Marketed products

13.14.2.2 Pipeline products

13.14.3 Key Financial Summary

13.15 Pfizer Inc.

13.15.1 Business Overview

13.15.2 Product and Service Offerings

13.15.2.1 Marketed products

13.15.2.2 Pipeline products:

13.15.3 Key Financial Summary

Chapter 14. Appendix

14.1 Abbreviations

14.2 Sources and References

14.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 IMMUNOTHERAPY PIPELINE DRUGS BY SANOFI

TABLE 3 IMMUNOTHERAPY PIPELINE DRUGS BY PFIZER INC.

TABLE 4 IMMUNOTHERAPY PIPELINE DRUGS BY NOVARTIS AG

TABLE 5 IMMUNOTHERAPY PIPELINE DRUGS BY MERCK & CO. INC.

TABLE 6 IMMUNOTHERAPY PIPELINE DRUGS BY JOHNSON & JOHNSON

TABLE 7 IMMUNOTHERAPY PIPELINE DRUGS BY GLAXOSMITHKLINE PLC

TABLE 8 IMMUNOTHERAPY PIPELINE DRUGS BY F. HOFFMAN-LA ROCHE LTD.

TABLE 9 IMMUNOTHERAPY PIPELINE DRUGS BY ELI LILLY AND COMPANY

TABLE 10 IMMUNOTHERAPY PIPELINE DRUGS BY CELGENE CORPORATION

TABLE 11 IMMUNOTHERAPY PIPELINE DRUGS BY C. H. BOEHRINGER SOHN AG & CO. KG

TABLE 12 IMMUNOTHERAPY PIPELINE DRUGS BY BRISTOL-MYERS SQUIBB COMPANY

TABLE 13 IMMUNOTHERAPY PIPELINE DRUGS BY ASTRAZENECA PLC

TABLE 14 IMMUNOTHERAPY PIPELINE DRUGS BY ABBVIE INC.

TABLE 15 SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE CANCER (MELANOMA)

TABLE 16 INTRAVENOUS IMMUNE GLOBULIN PRODUCTS LICENSED BY USFDA FOR THE TREATMENT OF INFECTIOUS DISEASES

TABLE 17 IMMUNOTHERAPEUTIC AGENTS UNDER CLINICAL STAGES FOR THE TREATMENT OF INFECTIOUS DISEASES

TABLE 18 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2013–2017)

TABLE 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2018–2023)

TABLE 20 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2013–2017)

TABLE 21 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2018–2023)

TABLE 22 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2013–2017)

TABLE 23 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2018–2023)

TABLE 24 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2013–2017)

TABLE 25 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2018–2023)

TABLE 26 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2017)

TABLE 27 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018–2023)

TABLE 28 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2017)

TABLE 29 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018–2023)

TABLE 30 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $B (2013–2017)

TABLE 31 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $B (2018–2023)

TABLE 32 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2017)

TABLE 33 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018–2023)

TABLE 34 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2017)

TABLE 35 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018–2023)

TABLE 36 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2017)

TABLE 37 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018–2023)

TABLE 38 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2017)

TABLE 39 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018–2023)

TABLE 40 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2017)

TABLE 41 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018–2023)

TABLE 42 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2017)

TABLE 43 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018–2023)

TABLE 44 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2017)

TABLE 45 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018–2023)

TABLE 46 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2017)

TABLE 47 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018–2023)

TABLE 48 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2017)

TABLE 49 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018–2023)

TABLE 50 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2017)

TABLE 51 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018–2023)

TABLE 52 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2017)

TABLE 53 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018–2023)

TABLE 54 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2017)

TABLE 55 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018–2023)

TABLE 56 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2017)

TABLE 57 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018–2023)

TABLE 58 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2017)

TABLE 59 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018–2023)

TABLE 60 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2017)

TABLE 61 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018–2023)

TABLE 62 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 63 ELI LILLY AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 64 SANOFI – AT A GLANCE

TABLE 65 SANOFI – KEY FINANCIAL SUMMARY

TABLE 66 NOVARTIS AG – AT A GLANCE

TABLE 67 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 68 ABBVIE INC. – AT A GLANCE

TABLE 69 ABBVIE INC. – KEY FINANCIAL SUMMARY

TABLE 70 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 71 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 72 ASTRAZENECA PLC – AT A GLANCE

TABLE 73 ASTRAZENECA PLC – KEY FINANCIAL SUMMARY

TABLE 74 MERCK & CO. INC. – AT A GLANCE

TABLE 75 MERCK & CO. INC. – KEY FINANCIAL SUMMARY

TABLE 76 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 77 GLAXOSMITHKLINE PLC – KEY FINANCIAL SUMMARY

TABLE 78 BRISTOL-MYERS SQUIBB COMPANY – AT A GLANCE

TABLE 79 BRISTOL-MYERS SQUIBB COMPANY – KEY FINANCIAL SUMMARY

TABLE 80 AMGEN INC. – AT A GLANCE

TABLE 81 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 82 C. H. BOEHRINGER SOHN AG & CO. KG – AT A GLANCE

TABLE 83 C. H. BOEHRINGER SOHN AG & CO. KG – KEY FINANCIAL SUMMARY

TABLE 84 CELGENE CORPORATION – AT A GLANCE

TABLE 85 CELGENE CORPORATION – KEY FINANCIAL SUMMARY

TABLE 86 JOHNSON & JOHNSON – AT A GLANCE

TABLE 87 JOHNSON & JOHNSON – KEY FINANCIAL SUMMARY

TABLE 88 TAKEDA PHARMACEUTICAL COMPANY LIMITED – AT A GLANCE

TABLE 89 TAKEDA PHARMACEUTICAL COMPANY LIMITED – KEY FINANCIAL SUMMARY

TABLE 90 PFIZER INC. – AT A GLANCE

TABLE 91 PFIZER INC. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 7 DATA TRIANGULATION APPROACH

FIG 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET SUMMARY

FIG 9 PREVALENCE OF MULTIPLE SCLEROSIS PER 100,000 PEOPLE IN EUROPEAN COUNTRIES (2015)

FIG 10 REIMBURSEMENT STATUS OF CANCER MEDICINES LAUNCHED DURING 2011–2015, IN SOME MAJOR COUNTRIES

FIG 11 IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST

FIG 12 IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST

FIG 13 BARGAINING POWER OF BUYERS

FIG 14 BARGAINING POWER OF SUPPLIERS

FIG 15 INTENSITY OF RIVALRY

FIG 16 THREAT OF NEW ENTRANTS

FIG 17 THREAT OF SUBSTITUTES

FIG 18 SNAPSHOT OF GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, (2017)

FIG 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2013–2023)

FIG 20 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2013–2023)

FIG 21 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2013–2023)

FIG 22 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2013–2023)

FIG 23 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2023)

FIG 24 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2023)

FIG 25 WORLDWIDE MAJOR MARKETS FOR IMMUNOTHERAPY DRUGS

FIG 26 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 27 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2023)

FIG 28 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2023)

FIG 29 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2023)

FIG 30 EUROPE IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 31 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2023)

FIG 32 HEALTHCARE DATA FOR SPAIN, DENMARK AND AUSTRIA (FOR THE YEARS 2000, 2008 & 2015)

FIG 33 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2023)

FIG 34 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2023)

FIG 35 APAC IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 36 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2023)

FIG 37 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2023)

FIG 38 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2023)

FIG 39 LATAM IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 40 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2023)

FIG 41 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2023)

FIG 42 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2023)

FIG 43 MEA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIG 44 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013–2023)

FIG 45 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013–2023)

FIG 46 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013–2023)

FIG 47 PRODUCT BENCHMARKING OF KEY PLAYERS

FIG 48 ELI LILLY AND COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)

FIG 49 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)

FIG 50 NOVARTIS AG – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)

FIG 51 ABBVIE INC. – REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)

FIG 52 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)

FIG 53 ASTRAZENECA PLC – REVENUE SPLIT BY THERAPY AREA AND GEOGRAPHY (2017)

FIG 54 MERCK & CO. INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)

FIG 55 GLAXOSMITHKLINE PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)

FIG 56 BRISTOL-MYERS SQUIBB COMPANY – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2017)

FIG 57 AMGEN INC. – REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)

FIG 58 C. H. BOEHRINGER SOHN AG & CO. KG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)

FIG 59 CELGENE CORPORATION – REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)

FIG 60 JOHNSON & JOHNSON – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)

FIG 61 TAKEDA PHARMACEUTICAL COMPANY LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2016)

FIG 62 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)